PMI
13.6.2019 12:39:03 CEST | Business Wire | Press release
Philip Morris International (PMI) today launches unsmokeyourworld.com , a new online hub for those that want to un smoke themselves or their loved ones, their communities, or the world. The website aims to provide an inspiring and engaging place to help people kick-start their smoke-free journeys. The best way to un smoke is to quit cigarettes and nicotine completely. For adult smokers that don’t the next best option is to switch to a better alternative.
A new survey conducted by Povaddo, commissioned by PMI, shows the potential to improve personal and social relationships by quitting cigarettes. Almost three-quarters—71 percent—of nonsmokers who are in a relationship with a smoking partner said they have had disagreements with their partner because he/she smokes cigarettes. The results showed even higher levels of disagreement in Israel, Italy and Russia, with 80 percent or more stating they have argued with their partner over smoking.
| Have you ever had a disagreement or argument with your partner or spouse because he/she smokes cigarettes? | |||||||||||||
|
Yes |
Russia | U.K. | U.S. | Hong Kong | Israel | Italy | |||||||
| 82% | 63% | 63% | 67% | 80% | 87% | ||||||||
| Japan | Mexico | Australia | Brazil | Denmark | Germany | ||||||||
| 55% | 77% | 68% | 72% | 56% | 55% | ||||||||
| Base: former and never smokers with a partner that smokes | |||||||||||||
Smokers, however, were less likely to recognize the impact that smoking has on their relationships with loved ones, with just, on average, 36 percent of them acknowledging that smoking has caused arguments with their loved ones.
| My smoking causes arguments with loved ones: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Strongly/ Somewhat agree | Russia | U.K. | U.S. | Hong Kong | Israel | Italy | |||||||||||||||||||||||||||||||||||||||||||||||||
| 38% | 32% | 32% | 42% | 43% | 43% | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Japan | Mexico | Australia | Brazil | Denmark | Germany | ||||||||||||||||||||||||||||||||||||||||||||||||||
| 22% | 43% | 25% | 62% | 8% | 22% | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
Base: current and occasional smokers.
Figures have been summed due to rounding |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
“This research shows the scale of the task ahead to help smokers understand the positive impact that unsmoking could have on their relationships,” said Jacek Olczak, Chief Operating Officer, PMI. “We believe that this type of insight should be made known to smokers so they can engage in a conversation and understand the benefits of getting behind the #unsmoke movement.”
Aiming to unify communities toward a smoke-free world, PMI’s unsmokeyourworld.com is an online hub where adult smokers and those that care about them can discover more about ways to un smoke. The site shares stories of un smoke heroes describing their smoke-free journeys and encourages readers to share their own stories.
Olczak continues: “Change comes from communities uniting behind a positive conversation, which is why we have created this place for people to come together and hear each other’s stories for inspiration. This is an important new tool for adult smokers and those who care about them so they can access resources to inspire them to leave cigarettes behind.”
Interactive elements engage readers to understand the facts behind unsmoking and allows them to publicly get involved. Users can add an ‘Un smoke Your World’ overlay to any image they want so they can show support on social media. They can also download and share a selection of gifs to celebrate un smoke successes.
Since April 2019, over 115,000 digital #unsmokeyourworld actions have taken place across the globe—ranging from individuals supporting the campaign on social media to engaging with digital content. PMI’s is calling for people to take action and create a strong movement to an un smoked world. For more information visit, unsmokeyourworld.com .
About the Povaddo Survey
This survey was carried out 24
April-6 May, 2019, by Povaddo, a leading public opinion research firm,
on behalf of Philip Morris International. The survey fielded a total of
16,099 online interviews among general population adults 21-74 years of
age across 13 countries (Argentina, Australia, Brazil, Denmark, Germany,
Hong Kong, Israel, Italy, Japan, Mexico, Russia, United Kingdom and
United States). The survey carries an overall margin of error of +/- 1%
at the 95 percent confidence interval.
About #Unsmokeyourworld
PMI is transforming its business and
increasing awareness of the urgent need to become smoke-free as well as
awareness of better alternatives for smokers who would otherwise
continue to smoke. PMI is producing smoke-free products that are a
better choice for smokers than continued cigarette smoking and can
benefit public health.
#Unsmoke is a PMI initiative to speed up an historic change in public health. Through the #unsmoke movement, we want to bring together a community of people who can accelerate this change by becoming advocates of the message that for smokers who would otherwise continue to smoke, there are better alternatives to choose from.
#Unsmokeyourworld is a global conversation that inspires human stories—for the people, by the people.
About Philip Morris International
Delivering a Smoke-Free
Future Philip Morris International (PMI) is leading a transformation in
the tobacco industry to create a smoke-free future and ultimately
replace cigarettes with smoke-free products to the benefit of adults who
would otherwise continue to smoke, society, the company and its
shareholders. PMI is a leading international tobacco company engaged in
the manufacture and sale of cigarettes, smoke-free products and
associated electronic devices and accessories, and other
nicotine-containing products in markets outside the U.S. PMI is building
a future on a new category of smoke-free products that, while not
risk-free, are a much better choice than continuing to smoke. Through
multidisciplinary capabilities in product development, state-of-the-art
facilities and scientific substantiation, PMI aims to ensure that its
smoke-free products meet adult consumer preferences and rigorous
regulatory requirements. For more information, please visit http://www.pmi.com
and www.pmiscience.com
.
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20190613005304/en/
Contact:
David Fraser Philip Morris International Media Office T. +41 (0)58 242 4500 E. david.fraser@pmi.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
